Sjögren

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
星期二, 五月 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Insurance, Patient, Ovarian cancer, Food, FDA, Marketing, NSCLC, DDC, PROC, Research, Pancreatic cancer, Cancer, Acquisition, Sjögren, Food and Drug Administration, NUVB, Pharmaceutical industry

Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
  • “The first quarter of 2024 included multiple significant events for Nuvation Bio.
  • As of March 31, 2024, Nuvation Bio had cash, cash equivalents and marketable securities of $597.0 million.
  • For the three months ended March 31, 2024, Nuvation Bio reported a net loss of $14.8 million, or $(0.07) per share.

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

Retrieved on: 
星期四, 三月 28, 2024
Biotechnology, General Health, Health, Pharmaceutical, Oncology, NUVB, Janssen Pharmaceuticals, Mirati Therapeutics, Event, Medivation, Patient, Bryant University, Cancer, Senior, Kite Pharma, Sjögren, Marketing, Pharmaceutical industry

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer.

Key Points: 
  • Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer.
  • Ms. Sjogren will lead the Company’s commercial strategy and operations, including marketing, sales, and market access.
  • “We are thrilled to welcome Colleen as Nuvation Bio’s first Chief Commercial Officer.
  • Of note, Colleen was one of my commercial superstars at Medivation when we launched XTANDI®,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio.

Sjogren's Syndrome Drug Pipeline Research Report 2023: Comprehensive Exploration of 20+ Companies and 25+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
星期一, 九月 4, 2023
Health, Pharmaceutical, Partnership, MorphoSys, TNF, ADCC, Survival, Clinical trial, NDA, Sjögren syndrome, Inflammation, Discovery, Monocyte, Novartis, Sjögren, BAFF-R, Horizon, CD40L, BAFF, News, FC, Family, B cell, III, Pharmaceutical industry, Vaccine, Phase

The "Sjogren's syndrome - Pipeline Insight, 2023" report offers a comprehensive exploration of the landscape, encompassing over 20 companies and more than 25 pipeline drugs within the realm of Sjogren's syndrome.

Key Points: 
  • The "Sjogren's syndrome - Pipeline Insight, 2023" report offers a comprehensive exploration of the landscape, encompassing over 20 companies and more than 25 pipeline drugs within the realm of Sjogren's syndrome.
  • The report not only sheds light on active pipeline products but also presents insights into inactive pipeline products within this domain.
  • Within this comprehensive report lies a detailed portrayal of the current landscape and the potential growth prospects within this therapeutic indication.
  • With an overview of Sjogren's syndrome treatment guidelines and disease overview, the report constructs a thorough picture of the Sjogren's syndrome pipeline landscape.

Cable Welcomes Candace Sjogren as Chief Revenue Officer

Retrieved on: 
星期一, 八月 7, 2023
Sjögren, LONDON, GTM, Kandake, Acquisition, Senior, SAN, Marketing, Cryptocurrency, Cable

SAN FRANCISCO & LONDON, Aug. 7 2023 /PRNewswire-PRWeb/ -- Cable, the all-in-one financial crime effectiveness testing platform, today announced that Candace Sjogren has joined the company as Chief Revenue Officer. Sjogren is a proven leader with significant experience in GTM strategy, sales, business development, and public relations in the financial services industry. She joins Cable as the company is poised to rapidly expand its customer base, market presence, and product portfolio following a successful $11 million Series A funding round earlier this year.

Key Points: 
  • SAN FRANCISCO & LONDON, Aug. 7 2023 /PRNewswire-PRWeb/ -- Cable , the all-in-one financial crime effectiveness testing platform, today announced that Candace Sjogren has joined the company as Chief Revenue Officer.
  • Sjogren is a proven leader with significant experience in GTM strategy, sales, business development, and public relations in the financial services industry.
  • With extensive experience and an impressive track record in leading high-performing revenue teams that consistently deliver strong results, Sjogren will play a pivotal role in the company's Go to Market strategy.
  • She will oversee revenue growth, customer acquisition, and marketing amid a rising market demand for Cable's platform.

Boeing Reorganizes Defense, Space & Security Business Unit

Retrieved on: 
星期四, 十一月 17, 2022
Argon, Boeing Defense, Space & Security, BDS, T-7, Total quality management, Government, DRT, BI, Safety, Security, Intelligence, Black supremacy, Boeing Phantom Works, NYSE, P-8, Culture, E-7, F-15, Kennedy Space Center Launch Complex 39, VC-25B, Weapon, BGS, Mobility, Sjögren, AWACS, Future Vertical Lift, Management, Airline, Bomber, Boeing, St. Louis

Effective immediately, Boeing Defense, Space & Security (BDS) will consolidate its eight divisions into four, including:

Key Points: 
  • Effective immediately, Boeing Defense, Space & Security (BDS) will consolidate its eight divisions into four, including:
    Vertical Lift, led by Vice President and General Manager Mark Cherry.
  • Between now and Feb. 4, 2023, Jim Chilton, senior vice president for Space and Launch, will continue to manage space exploration and launch programs, satellites and Phantom Works Space.
  • "I am confident this reorganization will drive greater and more simplified integration and collaboration across Boeing Defense, Space & Security," said Colbert.
  • As a leading global aerospace company, Boeing develops, manufactures and services commercial airplanes, defense products and space systems for customers in more than 150 countries.

EARLY GENETIC TESTING PREDICTS HEART DISEASE AND NOVEL THERAPIES FOR WOMEN WITH LUPUS

Retrieved on: 
星期五, 十一月 4, 2022
Precision medicine, Genetic testing, Oklahoma Office of the Chief Medical Examiner, RNA, Blood, Research, Biostatistics, Ageing, Algorithm, Database, Data science, Risk, IL6, Alliance for Lupus Research, Degenerative disease, Woman, FDA, Death, HSS, Infarction, Coronary artery disease, Atopic dermatitis, Wake Forest, Syndrome, Stroke, Machine learning, Smoke, CEO, CVD, Genetics, Sjögren syndrome, Physician, Cardiovascular disease, Psoriasis, ASD, Technology, Lung cancer, Lupus nephritis, Gene, Wake Forest School of Medicine, Cardiogenic shock, Patient, Wellness, Coalition, Sjögren, Female, Pharmaceutical industry, Vaccine, Lupus, Medicine, Fibromyalgia, Scleroderma

Shared genes that predispose both to lupus and cardiovascular disease are revealed in the peer-reviewed journal Cell Reports Medicine .

Key Points: 
  • Shared genes that predispose both to lupus and cardiovascular disease are revealed in the peer-reviewed journal Cell Reports Medicine .
  • AMPEL's innovative approach linking genetic predisposition to molecular pathways targeted by drugs may greatly impact health care by allowing physicians to identify cardiovascular disease risk following lupus diagnosis and select appropriate prophylactic treatments.
  • According to the Johns Hopkins Lupus Center, female lupus patients aged 35-44 are 50-times more likely to have a fatal cardiovascular event than other women in their age group.
  • One-third of all lupus deaths are due to unrecognized coronary artery disease leading to heart attacks and strokes.

AMPEL BioSolutions' Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning

Retrieved on: 
星期三, 七月 6, 2022
Lupus, Coalition, FDA, Autoimmunity, Patient, CEO, Conditional sentence, Sjögren syndrome, Lung cancer, Precision medicine, Gene, Emergency department, COVID, Biomarker, Population, Gene expression, Google, Cancer, Blood, Disease, Atopic dermatitis, Lupus nephritis, Sjögren, Machine learning, Degenerative disease, Pain, CSO, Chief medical informatics officer, Uraba lugens, Wellness, Publication, Syndrome, Clinical trial, Technology, Psoriasis, RNA, ASD, Quality of life, Computer, Time, Database, Big data, Infection, Drug development, Physician, Work, Multimedia, Algorithm, Century, Conference, Inflammation, Pharmaceutical industry, Medical device, Silicon, Fibromyalgia, Pharma, Scleroderma

CHARLOTTESVILLE, Va., July 6, 2022 /PRNewswire/ --  AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer. Revealed at the Precision Medicine World Conference in Silicon Valley California, the first-in-class platform technology utilizes RNA analytics and machine learning to characterize an individual's gene expression and provide clinical decision support to physicians for treatment options for their patients.  The technology, only a concept for the last few years, is being utilized to launch a portfolio of 10+ clinical tests over the next five years to provide decision support for diseases that affect more than 50 million Americans.

Key Points: 
  • Revealed at the Precision Medicine World Conference in Silicon Valley California, the first-in-class platform technology utilizes RNA analytics and machine learning to characterize an individual's gene expression and provide clinical decision support to physicians for treatment options for their patients.
  • The application of AMPEL's technology is already assisting 15+ pharmaceutical companies in drug development and clinical trials.
  • Dr.Amrie Grammer, AMPEL Co-Founder, President and CSO:""Our team has developed a genomic platform technology with machine learning that supports clinical precision medicine tests that predict drug options based on gene expression.
  • AMPEL BioSolutions was elected to the Coalition for 21st Century Precision Medicine in early 2022.

Boeing and Rossell Techsys - A Partnership of 100,000 Deliveries and Going Strong

Retrieved on: 
星期二, 六月 7, 2022
DHS Chemical and Biological Defense Division, Achievement, Boeing AH-64 Apache, Electrical wiring interconnection system, F-15, Partnership, Apache, International, LEED, Centre for International Governance Innovation, Leadership in Energy and Environmental Design, Sjögren, Bell Boeing V-22 Osprey, Gold, Aerospace, Center, Boeing T-7 Red Hawk, Electricity, Supply chain management, COE, Boeing F/A-18E/F Super Hornet, CSR, Boeing CH-47 Chinook, Airline, Boeing

BENGALURU, India, June 7, 2022 /PRNewswire/ -- Rossell Techsys today announced the completion of 100,000 deliveries to Boeing for its various platforms, including 50,000 deliveries for the Apache platform alone.

Key Points: 
  • BENGALURU, India, June 7, 2022 /PRNewswire/ -- Rossell Techsys today announced the completion of 100,000 deliveries to Boeing for its various platforms, including 50,000 deliveries for the Apache platform alone.
  • Rossell Techsys has manufactured these parts at their state-of-the-art Centre of Excellence (COE) facility in Devanahalli, Bangalore.
  • Mr. Torbjorn (Turbo) Sjogren, Vice President, International Government & Defence, Boeing Global Services; Mr. Ashwani Bhargava, Senior Director, India Supplier Management; Mr. Rishab Gupta, Director, Rossell India Ltd., and other Boeing and Rossell Techsys executives were present to mark the delivery milestone.
  • We value our partnership with Boeing and the encouragement given to us to work on many prestigious Boeing platforms," said Mr. Rishab Gupta, Director, Rossell Techsys.

Boeing and Rossell Techsys - A Partnership of 100,000 Deliveries and Going Strong

Retrieved on: 
星期一, 六月 6, 2022
DHS Chemical and Biological Defense Division, Achievement, Boeing AH-64 Apache, Electrical wiring interconnection system, F-15, Partnership, Apache, International, Multimedia, LEED, Centre for International Governance Innovation, Leadership in Energy and Environmental Design, Sjögren, Bell Boeing V-22 Osprey, Gold, Aerospace, Center, Boeing T-7 Red Hawk, Electricity, Supply chain management, COE, Boeing F/A-18E/F Super Hornet, CSR, Boeing CH-47 Chinook, Airline, Boeing

BENGALURU, India, June 6, 2022 /PRNewswire/ -- Rossell Techsys today announced the completion of 100,000 deliveries to Boeing for its various platforms, including 50,000 deliveries for the Apache platform alone.

Key Points: 
  • BENGALURU, India, June 6, 2022 /PRNewswire/ -- Rossell Techsys today announced the completion of 100,000 deliveries to Boeing for its various platforms, including 50,000 deliveries for the Apache platform alone.
  • Rossell Techsys has manufactured these parts at their state-of-the-art Centre of Excellence (COE) facility in Devanahalli, Bangalore.
  • Mr. Torbjorn (Turbo) Sjogren, Vice President, International Government & Defence, Boeing Global Services; Mr. Ashwani Bhargava, Senior Director, India Supplier Management; Mr. Rishab Gupta, Director, Rossell India Ltd., and other Boeing and Rossell Techsys executives were present to mark the delivery milestone.
  • We value our partnership with Boeing and the encouragement given to us to work on many prestigious Boeing platforms," said Mr. Rishab Gupta, Director, Rossell Techsys.

Europe Sjogren's Syndrome Market and Competitive Landscape Research Report 2021: Pipeline, Epidemiology, Valuations, Drug Sales, Drug Forecasts, & Market Shares 2018-2026 - ResearchAndMarkets.com

Retrieved on: 
星期三, 三月 16, 2022
Health, Pharmaceutical, Epidemiology, Sjögren, Competitive landscape, Prevalence, Syndrome, Research, Sjögren syndrome, Pharmaceutical industry

The "Europe Sjogren's Syndrome Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Sjogren's Syndrome Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Europe Sjogren's Syndrome Market and Competitive Landscape - 2021, provides comprehensive insights into Sjogren's Syndrome pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Sjogren's Syndrome treatment options, Sjogren's Syndrome late-stage clinical trials pipeline, Sjogren's Syndrome prevalence by countries, Sjogren's Syndrome market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Sjogren's Syndrome pipeline: Find out drugs in clinical trials for the treatment of Sjogren's Syndrome by development phase 3, phase 2, by pharmacological class and company
    Sjogren's Syndrome drugs: Identify key drugs marketed and prescribed for Sjogren's Syndrome in the US, including trade name, molecule name, and company
    Sjogren's Syndrome market valuations: Find out the market size for Sjogren's Syndrome drugs in 2020 by countries.